Anavex Life Sciences Corp. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AVXL Nasdaq 2836 www.anavex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Anavex Life Sciences Corp.

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - Dec 12th, 2025 2:05 pm
Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) - Dec 2nd, 2025 7:35 am
Anavex Life Sciences And 2 Other Promising Penny Stocks To Watch - Nov 27th, 2025 5:04 am
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference - Nov 26th, 2025 5:30 am
Anavex (AVXL) Q4 2025 Earnings Call Transcript - Nov 25th, 2025 3:11 pm
Anavex Life Sciences Corp (AVXL) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... - Nov 25th, 2025 2:00 pm
Anavex Life Sciences: Fiscal Q4 Earnings Snapshot - Nov 25th, 2025 5:47 am
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update - Nov 25th, 2025 5:30 am
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference - Nov 19th, 2025 5:30 am
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 - Nov 18th, 2025 5:30 am
Why Anavex Life Sciences (AVXL) Is Down 43.8% After EMA Setback for Lead Alzheimer’s Drug - Nov 17th, 2025 2:10 am
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease - Nov 14th, 2025 5:30 am
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group - Oct 29th, 2025 5:30 am
US High Growth Tech Stocks To Watch For Potential Expansion - Oct 16th, 2025 11:38 am
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’ - Oct 10th, 2025 5:30 am
Sector Update: Health Care Stocks Retreat Late Afternoon - Oct 2nd, 2025 1:58 pm
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program - Oct 2nd, 2025 5:35 am
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - Oct 2nd, 2025 5:30 am
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial - Sep 30th, 2025 6:30 am
H.C. Wainwright Reiterates Its ‘Buy’ Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target - Sep 24th, 2025 6:38 pm